```html

Nephrotic Syndrome (Minimal Change Disease)

Overview

Nephrotic syndrome is a collection of signs that indicate a problem with the kidney’s filtering units (glomeruli). The most common cause of nephrotic syndrome in children—and a frequent cause in adults—is Minimal Change Disease (MCD). The disease is called “minimal change” because the kidney tissue looks almost normal under a regular microscope; the damage is only visible with an electron microscope.

Who it affects

• Children: About 80–90 % of nephrotic syndrome cases in kids aged 1–10 years are due to MCD.
• Adults: MCD accounts for roughly 10–15 % of adult nephrotic syndrome cases, with a slight male predominance.

Prevalence

• Incidence in children: 2–7 per 100,000 per year (CDC, 2023).
• Adult incidence: 1–2 per 100,000 per year (NIH, 2022).
• Overall, nephrotic syndrome affects ~5–10 per 100,000 people worldwide.

Symptoms

Symptoms arise from massive protein loss in the urine, low protein levels in the blood, and the body’s response to fluid shifts. Not every patient will have all of them.

Key clinical features

• Edema – swelling, usually first noticeable around the eyes (periorbital) in the morning, then in the ankles, feet, abdomen (ascites), and sometimes the hands.
• Proteinuria – urine that contains >3.5 g of protein per 24 hours (often “frothy” or “foamy”).
• Hypoalbuminemia – low blood albumin (<2.5 g/dL) causing fluid to leak out of vessels.
• Hyperlipidemia – elevated cholesterol and triglycerides, which can make the skin appear oily or lead to xanthomas.
• Weight gain – rapid gain due to fluid retention rather than fat.

Additional symptoms that may appear

• Fatigue or generalized weakness.
• Foamy urine (visible bubbles).
• Decreased urine output (oliguria) if kidney function declines.
• Infections – especially peritonitis or cellulitis, because low immunoglobulin levels accompany protein loss.
• Blood clots (deep‑vein thrombosis) – protein loss includes antithrombin III, raising clot risk.
• In children, the disease may present after a recent viral infection or an allergic reaction.

Causes and Risk Factors

The exact mechanism that triggers the “minimal change” pattern is not fully understood, but research points to an immune‑mediated process that damages the podocytes (specialized cells that line the glomerular basement membrane).

Known or suspected causes

• Immune dysregulation – T‑cell dysfunction leading to the release of a circulating permeability factor.
<
• Allergies or recent infections – Upper‑respiratory viruses, hepatitis B, or streptococcal infections sometimes precede onset.
• Medications – NSAIDs, lithium, or certain antibiotics have been linked to secondary MCD.
• Vaccinations – Rarely, MCD can appear after immunizations (e.g., influenza, hepatitis B), though the benefit of vaccination far outweighs the risk.

Risk factors

• Age 1–10 years (peak incidence).
• Male sex (especially in children).
• History of atopy (eczema, asthma, allergic rhinitis).
• Recent viral infection or immunization.
• Use of medications known to affect podocyte function.

Diagnosis

Diagnosing MCD involves confirming the classic nephrotic picture and ruling out other causes of proteinuria.

Initial laboratory evaluation

• Urinalysis – shows heavy proteinuria, possible hematuria, and lipiduria (fatty casts).
• 24‑hour urine protein – ≥3.5 g confirms nephrotic‑range protein loss.
• Serum albumin – typically <2.5 g/dL.
• Lipid profile – elevated total cholesterol & triglycerides.
• Renal function tests – serum creatinine & eGFR; usually normal early in MCD.
• Immunologic labs – complement levels, ANA, anti‑DNA to exclude lupus nephritis.

Imaging

• Renal ultrasound – generally normal; performed to rule out structural kidney disease.

Kidney biopsy

While not always required in children with classic presentation, a biopsy is the gold standard when:

• There is atypical presentation (e.g., hematuria, reduced kidney function).
• Patients are adults, where other glomerular diseases are more common.
• Response to steroids is poor (<2 weeks).

On light microscopy the tissue appears normal; electron microscopy demonstrates podocyte foot‑process effacement.

Diagnostic criteria (summary)

1. Nephrotic‑range proteinuria (≥3.5 g/24 h).
2. Hypoalbuminemia (<3 g/dL).
3. Peripheral edema.
4. Hyperlipidemia.
5. Histology consistent with minimal change (if biopsy performed).

Treatment Options

Therapy aims to induce remission, prevent relapses, and manage complications.

First‑line medication: Corticosteroids

• Prednisone 2 mg/kg/day (max 60 mg) for 4–6 weeks, followed by a taper over 2–6 months.
• ~80–90 % of children achieve complete remission within 2 weeks; adults respond in ~70 %.
• Monitor for side effects: hyperglycemia, hypertension, weight gain, mood changes, osteoporosis.

Steroid‑sparing agents (used for frequent relapsers or steroid‑resistant disease)

• Calcineurin inhibitors – Cyclosporine or Tacrolimus; dose adjusted to therapeutic trough levels.
• Mycophenolate mofetil (MMF) – 1–2 g/day divided doses.
• Rituximab – Anti‑CD20 monoclonal antibody; 375 mg/m² weekly for 4 weeks in refractory cases.
• Evidence from randomized trials supports rituximab for steroid‑dependent MCD (Cleveland Clinic, 2021).

Supportive care

• Diuretics (e.g., furosemide) to control edema; monitor electrolytes.
• ACE inhibitors or ARBs – reduce proteinuria and protect renal function.
• Lipid‑lowering agents – statins for persistent hyperlipidemia.
• Anticoagulation – consider prophylactic low‑dose anticoagulation if serum albumin <2 g/dL or prior thrombosis.
• Vaccinations – pneumococcal, influenza, and hepatitis B (inactivated forms) to reduce infection risk.

Lifestyle and dietary measures

• Low‑salt diet (≤2 g sodium/day) to limit fluid retention.
• Maintain adequate protein intake (0.8–1 g/kg/day) – not overly restrictive, as protein loss is already high.
• Fluid restriction only if severe edema or heart failure (<1.5 L/day).
• Weight‑bearing exercise as tolerated; avoid prolonged immobilization (reduces clot risk).

Living with Nephrotic Syndrome (Minimal Change Disease)

Successful long‑term management combines medical therapy with daily habits that support kidney health.

Daily self‑monitoring

• Weigh yourself each morning; note a gain of >2 kg (≈4.5 lb) as a sign of fluid accumulation.
• Check for swelling in ankles, face, or abdomen.
• Observe urine for frothiness; write down any changes.
• Record blood pressure at least twice a week (target <130/80 mm Hg).

Medication adherence

Set alarms or use a pill‑box; keep a list of all drugs (including over‑the‑counter) to share with every healthcare provider.

Nutrition tips

• Choose fresh fruits, vegetables, whole grains, and lean proteins.
• Limit processed foods high in saturated fat and sodium.
• Stay hydrated, but follow fluid recommendations from your doctor.

Physical activity

Gentle aerobic activity (walking, swimming) 30 minutes most days improves cardiovascular health and reduces clot risk. Discuss any new exercise plan with your nephrologist.

Psychosocial support

Children may miss school; adults may feel fatigued or anxious. Access counseling, support groups, or patient organizations such as the National Kidney Foundation.

Regular follow‑up

• Every 1–3 months while on steroids; then every 3–6 months after remission.
• Lab checks each visit: urine protein, serum albumin, cholesterol, kidney function, and, if on calcineurin inhibitors, drug levels.

Prevention

Because MCD is largely idiopathic, primary prevention is limited. However, you can reduce triggers and complications:

• Promptly treat respiratory infections; avoid unnecessary antibiotic use.
• Manage underlying allergic conditions (e.g., eczema) with appropriate therapy.
• Limit exposure to known nephrotoxic drugs (NSAIDs, certain antibiotics) unless medically necessary.
• Maintain a healthy weight and blood pressure to protect overall kidney health.

Complications

If left untreated or poorly controlled, nephrotic syndrome can lead to serious health problems:

• Acute kidney injury (AKI) – from severe hypovolemia or interstitial inflammation.
• Infections – especially peritonitis, cellulitis, and pneumococcal pneumonia.
• Thromboembolic events – deep‑vein thrombosis, renal vein thrombosis, pulmonary embolism.
• Hyperlipidemia‑related atherosclerosis – accelerated cardiovascular disease.
• Malnutrition – loss of proteins and fats leading to growth failure in children.
• Steroid‑related side effects – osteoporosis, cataracts, diabetes, growth retardation.
• Progression to chronic kidney disease (CKD) – rare in pure MCD but possible with repeated relapses or superimposed injury.

When to Seek Emergency Care

---

Sources: Mayo Clinic. “Nephrotic syndrome.” 2023; CDC. “Kidney disease in the United States.” 2023; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). 2024; Cleveland Clinic. “Rituximab for steroid‑dependent minimal change disease.” 2021; WHO. “Guidelines for the management of chronic kidney disease.” 2022.

```